2026 Jun 19
Psychedelics Part 2: For patients facing life-threatening illness, distress can involve fear, grief, uncertainty, and questions of meaning. In Part 2, we speak with Dr. Emma Hapke from the Psychedelic Psychotherapy Research Group at UHN about psilocybin-assisted psychotherapy for end-of-life distress in patients with advanced cancer and their caregivers. We also hear from Daryna, who shares her perspective as a patient and reflects on the human side of navigating serious illness. Together, these conversations highlight both the promise and complexity of psychedelic-assisted therapy.
Psychiatrist and psychotherapist at the University Health Network in Toronto; specializes in psychedelic-assisted psychotherapy
Registered psychotherapist; advocate for psychedelic-assisted therapy in Canada; specializes in psychedelic therapy as a palliative and spiritual care model for patients facing terminal illness, trauma, and end-of-life distress
Coming soon!
